MDGL
$315.79
Revenue | $137.25Mn |
Net Profits | $-73.24Mn |
Net Profit Margins | -53.36% |
Madrigal Pharmaceuticals, Inc.’s revenue jumped +Inf% since last year same period to $137.25Mn in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 32.84% jump in its revenue since last 3-months.
Madrigal Pharmaceuticals, Inc.’s net profit jumped 50.36% since last year same period to $-73.24Mn in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated -23.26% fall in its net profits since last 3-months.
Madrigal Pharmaceuticals, Inc.’s net profit margin jumped NaN% since last year same period to -53.36% in the Q1 2025. On a quarterly growth basis, Madrigal Pharmaceuticals, Inc. has generated 7.21% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -3.36 |
EPS Estimate Current Year | -3.36 |
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current quarter stand at -3.36 - a 5.88% jump from last quarter’s estimates.
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) estimates for the current year stand at -3.36.
Earning Per Share (EPS) | 0 |
Madrigal Pharmaceuticals, Inc.’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q2 2025. This indicates that the Madrigal Pharmaceuticals, Inc. has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2025-08-06 | -3.57 | 0 | 100% |
2025-05-01 | -6.28 | -3.32 | 47.13% |